The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers ; volume:7 ; number:1 ; day:06 ; month:8 ; year:2007 ; pages:1-11 ; date:12.2007
BMC cancer ; 7, Heft 1 (06.8.2007), 1-11, 12.2007
- Creator
-
Friedenson, Bernard
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-7-152
- URN
-
urn:nbn:de:1111-2016030343018
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Friedenson, Bernard
- SpringerLink (Online service)
Other Objects (12)
Standardized assays to monitor drug sensitivity in hematologic cancers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Hematologic markers of distant metastases and poor prognosis in gynecological cancers
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
Endometrial cancers
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers
Embryonic mammary signature subsets are activated in Brca1 -/- and basal-like breast cancers
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
Mendelian randomization analysis reveals the combined effects of epigenetics and telomere biology in hematologic cancers
Standardized assays to monitor drug sensitivity in hematologic cancers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Hematologic markers of distant metastases and poor prognosis in gynecological cancers
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
Endometrial cancers
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers
Embryonic mammary signature subsets are activated in Brca1 -/- and basal-like breast cancers
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
Mendelian randomization analysis reveals the combined effects of epigenetics and telomere biology in hematologic cancers
Standardized assays to monitor drug sensitivity in hematologic cancers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Hematologic markers of distant metastases and poor prognosis in gynecological cancers
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
Endometrial cancers
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers
Embryonic mammary signature subsets are activated in Brca1 -/- and basal-like breast cancers
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers